Acumen Pharmaceuticals Inc
(NAS:ABOS)
$
3
0.05 (1.69%)
Market Cap: 180.24 Mil
Enterprise Value: -55.02 Mil
PE Ratio: 0
PB Ratio: 0.74
GF Score: 36/100 
Acumen Pharmaceuticals Inc at UBS BioPharma Conference Transcript
Nov 09, 2023 / 03:00PM GMT
Release Date Price:
$1.86
(-8.82%)
Colin Nigel Bristow
UBS Investment Bank, Research Division - Analyst
Good morning, and welcome to the UBS Biopharma Conference. I'm Colin Bristow, one of the biotech analysts. My pleasure to have Acumen Pharmaceuticals with us here today. On behalf of the company, we have Dan O'Connell, President and CEO. Dan, thanks for being with us today.
Daniel J. O;Connell
Acumen Pharmaceuticals, Inc. - CEO, President & Director
' -
Thanks, Colin.
Colin Nigel Bristow
UBS Investment Bank, Research Division - Analyst
So it's great to have you here sort of right after CTAD and some really interesting developments in the overall Alzheimer's space. Obviously, you guys had a presence at CTAD, some interesting updates. Before we sort of dig into 193, just what were some of the sort of most interesting takeaways for the field that you walked away with?
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers